Novel cancer therapeutic strategies to target RCAS1

RCAS1可以诱导免疫细胞凋亡，包括外周淋巴细胞和自然杀伤细胞，经外胞域脱落转化为分泌型。由于RCAS1不仅可以帮助肿瘤细胞逃避免疫监视，还可以诱导肿瘤间质组织重塑，因此RCAS1被认为可以夸大人类恶性肿瘤的侵袭性特征。在临床上，RCAS1表达与肿瘤大小、分期、浸润深度和淋巴结转移等多个病理变量相关，并且在15种不同类型的癌症中是总生存的负向预测因子。针对一种有趣的生物标志物RCAS1，新的癌症治疗策略正在开发中。

RCAS1 can induce apoptosis in immune cells including peripheral lymphocytes and natural killer cells after converted to a secreted type by ectodomain shedding. Because RCAS1 not only helps tumor cells to evade immune surveillance but also induces cancer stromal tissue remodeling, RCAS1 is believed to exaggerate aggressive characteristics of human malignancies. Clinically, RCAS1 expression correlates with several pathological variables including tumor size, stage, invasion depth, and lymph node metastasis and is a negative predictor of overall survival in 15 different kinds of cancer. Novel therapeutic strategies against cancer are now under development by targeting an intriguing biomarker RCAS1.